新开河品牌怎么样 申请店铺

我要投票 新开河在人参行业中的票数:117 更新时间:2025-02-23
新开河是哪个国家的品牌?「新开河」是 康美药业股份有限公司 旗下著名品牌。该品牌发源于吉林省通化市,由创始人马董在1997年期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力新开河品牌出海!通过在本页面挂载新开河品牌的产品链接和联系邮箱,可以提高新开河产品曝光!跨境电商爆单神器,目前只要100元/年哦~

新开河怎么样

成立于1997年,较早布局中医药全产业,以中药饮片为核心,以智慧药房为抓手,打造大健康+大平台+大数据+大服务体系


康美药业股份有限公司(600518)成立于1997年,于2001年在上交所上市。公司秉承“心怀苍生、大爱无疆”的核心价值观和“用爱感动世界、用心经营健康”的经营理念,在国家振兴中医药事业战略指引下,较早布局中医药全产业,以中药饮片为核心,以智慧药房为抓手,打造“大健康+大平台+大数据+大服务”体系,成为中医药全产业链服务型“智慧+”大健康产业上市企业。

康美药业上至药材种植、药材交易,下至生产开发、终端销售,已基本贯穿中医药产业链的上、中、下游产业,业务渗透中医药全产业链的各个关键环节,有效地整合全产业链资源。公司先后在全国各地投资建立140多家涵盖药材种植、中药材交易市场、现代物流中心和产业基地等业务的企业。

在全国建立了17个中药饮片和医药现代化生产基地,与超过2000家医疗机构、20万家药店建立了合作关系,年门诊总量达到2.5亿人次以上,投资管理康美医院、康美梅河口中心医院、康美通辽医院、康美开原市中心医院、康美通城人民医院、康美柳河中心医院等多家公立医院,在100多家公立医院开展医药物流延伸配送服务。

公司以国家中医药管理局信息化医疗服务平台试点单位为契机,把互联网深度布局全产业链中,以中药饮片为核心,以智慧药房为抓手,围绕“大健康+大平台+大数据+大服务”体系,以全产业链资源优势,积极探索中医药工业智能制造4.0,较早打造“智慧药房”模式。“智慧药房”模式上升为行业标准,为患者提供了“一站式”药事服务。截止2018年三季度,康美智慧药房累计处方量710万张,服务患者250万人,实现了“让信息多跑路,让群众少跑腿”。

康美药业丰富的医疗资源为公司以互联网思维、技术,改造和升级传统医疗健康产业,打造具有优良用户体验、覆盖全生命周期、一站式完整医疗服务闭环的移动健康管理大平台,奠定了坚实的基础。


Founded in 1997, Kangmei Pharmaceutical Co., Ltd. (600518) was founded in 1997 and listed on the Shanghai Stock Exchange in 2001. It has an early layout of the whole industry of traditional Chinese medicine, with herbal pieces as the core and smart pharmacies as the starting point to build a big health + big platform + big data + big service system. The company adheres to the core values of "caring for the world, loving the boundless" and the business philosophy of "moving the world with love and managing health with heart". Under the guidance of the national strategy of rejuvenating the cause of traditional Chinese medicine, the whole industry of traditional Chinese medicine is laid out earlier, with Chinese herbal pieces as the core and smart pharmacies as the starting point, and the system of "big health + big platform + big data + big service" is built to become the whole industry of traditional Chinese medicine Chain service-oriented "wisdom +" large health industry listed enterprises. Kangmei pharmaceutical industry has basically run through the upstream, midstream and downstream industries of TCM industry chain from the planting and trading of medicinal materials to the production and development and terminal sales. Its business penetrates all key links of the whole industry chain of TCM and effectively integrates the resources of the whole industry chain. The company has successively invested and established more than 140 enterprises covering medicine planting, Chinese medicine trading market, modern logistics center and industrial base. It has established 17 modern production bases of Chinese herbal pieces and medicine, established cooperative relations with more than 2000 medical institutions and 200000 pharmacies, with an annual outpatient volume of more than 250 million person times, invested and managed many hospitals, including Kangmei hospital, Kangmei Meihekou Central Hospital, Kangmei Tongliao hospital, Kangmei Kaiyuan Central Hospital, Kangmei Tongcheng people's Hospital and Kangmei Liuhe central hospital Public hospitals, in more than 100 public hospitals to carry out pharmaceutical logistics extended distribution services. Taking the opportunity of the pilot unit of the informatization medical service platform of the State Administration of traditional Chinese medicine, the company takes the Internet as an in-depth layout in the whole industry chain, with Chinese herbal pieces as the core, smart pharmacy as the starting point, around the "big health + big platform + big data + big service" system, and with the resource advantages of the whole industry chain, actively explores the intelligent manufacturing 4.0 of the traditional Chinese medicine industry, and builds the "smart pharmacy" model earlier Type. The mode of "smart pharmacy" has risen to the industry standard, providing patients with "one-stop" pharmaceutical services. As of the third quarter of 2018, Kangmei smart pharmacy has accumulated 7.1 million prescriptions, served 2.5 million patients, and realized "let more information run more, let the masses run less". Kangmei pharmaceutical's rich medical resources have laid a solid foundation for the company to transform and upgrade the traditional medical and health industry with internet thinking and technology, and to build a mobile health management platform with excellent user experience, covering the whole life cycle and one-stop complete medical service closed-loop.

本文链接: https://brand.waitui.com/f1e75a350.html 联系电话:请联系客服添加

千城特选小程序码

7×24h 快讯

天岳先进:2024年净利润1.8亿元 同比扭亏为盈

36氪获悉,天岳先进发布业绩快报,公司2024年实现营业收入17.68亿元,同比增长41.37%;实现归属于母公司所有者的净利润1.80亿元,同比扭亏为盈。主要原因是公司大尺寸、导电型产品产能产量持续提升,销售量增加,同时产品毛利率上升。

2小时前

小米集团卢伟冰:小米15 Ultra会是越级式的一代产品

36氪获悉,小米集团合伙人兼总裁、手机部总裁、小米品牌总经理卢伟冰发文称,小米手机未来5年高端化的目标之一,就是要在6000元+价格段实现规模化的突破,“Ultra是6K+突破的关键产品,而小米15 Ultra会是越级式的一代产品”。

2小时前

恒瑞医药:羟乙磺酸达尔西利片联合内分泌治疗乳腺癌III期临床试验达主要终点

36氪获悉,恒瑞医药公告称,公司自主研发的羟乙磺酸达尔西利片在激素受体(HR)阳性、人表皮生长因子受体2(HER2)阴性女性乳腺癌辅助治疗的III期临床试验中,首次期中分析主要终点达到统计学显著性。研究结果显示,达尔西利联合内分泌治疗可显著降低患者复发风险,提高患者无侵袭性疾病生存期(IDFS)。公司已向国家药品监督管理局药品审评中心递交上市前沟通交流申请。该药品是公司自主研发的化学药品1类新药,是一种口服、高效、选择性的小分子CDK4/6抑制剂。

2小时前

深圳:近期将发布人形机器人专项政策 在全市科技重大专项中安排人工智能和机器人专项

深圳市政府新闻办2月23日召开“打造最好科技创新生态和人才发展环境”主题新闻发布会。市人工智能产业办主任林毅在会上表示,深圳在人工智能和机器人领域基础雄厚、未来可期。下一步,我们将在政策、场景、创新、机器人四个方面持续发力。此外,近期我们还将发布人形机器人专项政策,通过“揭榜挂帅”等方式,对开放应用场景、突破关键技术、构建专用数据集、提升规模化制造和应用能力等予以精准支持。同时,还将在全市科技重大专项中安排人工智能和机器人专项,鼓励产、学、研、用组成创新联合体进行协同攻关。(财联社)

2小时前

一汽大众ID.系列部分车型官降至高5.5万元

一汽-大众宣布对旗下ID.系列部分车型进行降价,最高降幅达5.5万元。此次降价活动涉及ID.4 CROZZ和ID.6 CROZZ两款车型,无门槛一口价分别为13.99万元和19.59万元起,还可叠加官方置换补贴至高1万元、国家置换补贴至高2万元。(财联社)

2小时前

本页详细列出关于吉韩庄的品牌信息,含品牌所属公司介绍,吉韩庄所处行业的品牌地位及优势。
咨询